# Vestibular Versus Sublingual Route of AIT Tablets

> **NCT05119751** · PHASE4 · COMPLETED · sponsor: **Clinique Spécialisée en Allergies de la Capitale** · enrollment: 172 (actual)

## Conditions studied

- Hypersensitivity

## Interventions

- **DRUG:** tree 12 SQ-Bet
- **DRUG:** GRASS 2800 BAU
- **DRUG:** RAGWEED 12 AMB A 1-U
- **DRUG:** HDM 12 SQ-HDM

## Key facts

- **NCT ID:** NCT05119751
- **Lead sponsor:** Clinique Spécialisée en Allergies de la Capitale
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2021-10-25
- **Primary completion:** 2022-04-05
- **Final completion:** 2022-04-21
- **Target enrollment:** 172 (ACTUAL)
- **Last updated:** 2022-06-02

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05119751

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05119751, "Vestibular Versus Sublingual Route of AIT Tablets". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT05119751. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*